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POTENSI KESAN ANTIKANSER DAUN PSIDIUM GUAJAVA (JAMBU 





 Kanser kolorektal, iaitu kanser yang terdapat dalam kolon atau rektum, adalah 
salah satu kanser yang mengakibatkan kematian yang paling umum. Kelaziman kanser 
kolorektal di Malaysia dijangka akan meningkat disebabkan oleh penuaan populasi, 
kemajuan sosioekonomi, serta diet dan gaya hidup yang semakin kebaratan. 
Pertumbuhan tumor-tumor kolorektal melebihi saiz tertentu, serta penyebaran 
metastatik mereka, bergantung kepada peningkatan angiogenesi di vaskulatur 
sekitarnya. Disebabkan daun-daun Psidium guajava (jambu batu) kaya dengan 
sebatian fenolik, flavonoid, karotenoid, dan vitamin, aktiviti-aktiviti anti-angiogenik 
dan antikanser ekstrak-ekstrak daun P. guajava diselidiki untuk menilai potensi 
mereka dalam rawatan kanser kolorektal yang bergantung kepada angiogenesis. Tiga 
ekstrak dihasilkan menggunakan air suling, etanol, dan n-heksana sebagai pelarut, dan 
dilabelkan sebagai dH2O, EOH, dan NH. Ekstrak-ekstrak tersebut dicirikan secara 
fizikal melalui kromatografi gas-spektrometer massa (GC-MS), spektroskopi 
ultraviolet dan sinar tampak (UV-Vis), dan spektroskopi inframerah transformasi 
Fourier (FTIR). Melalui kajian pemulung radikal bebas DPPH, jumlah kandungan 
fenolik, dan jumlah kandungan flavonoid, ekstrak EOH didapati mempunyai aktiviti 
antioksidan yang tertinggi. Ekstrak dH2O dan EOH menunjukkan aktiviti perencatan 
yang lebih banyak terhadap daya maju sel-sel EA.hy926 (endothelial vaskular manusia) 
dan pertumbuhan saluran darah mikro dari cincin aortik tikus berbanding dengan 
ekstrak NH, menunjukkan aktiviti anti-angiogenik yang lebih baik. Untuk mengkaji 
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kesan-kesan ekstrak dH2O dan EOH ke atas pelbagai aspek proses angiogenik, kajian-
kajian penghijrahan sel, pembentukan tiub, dan pembentukan koloni telah dijalankan 
menggunakan sel-sel EA.hy926. Ekstrak EOH didapati jauh lebih baik daripada 
ekstrak dH2O dari segi menentang penghijrahan sel dan pembentukan koloni sel-sel. 
Kedua-dua ekstrak juga berkesan terhadap pembentukan tiub, dengan ekstrak dH2O 
yang mempunyai aktiviti perencatan yang lebih tinggi. Melalui kajian penetapan kadar 
imunosorben taut-enzim (ELISA), ekstrak EOH didapati berjaya menghalang ekspresi 
VEGF dari sel-sel EA.hy926. Ekstrak NH mempunyai aktiviti ingibisi yang lebih baik 
terhadap sel-sel karsinoma kolon HCT 116, walaupun nilai IC50 yang tinggi 
menunjukkan bahawa ketiga-tiga ekstrak tersebut tidak sitotoksik terhadap sel-sel 
kanser, dan ekstrak-ekstrak tersebut mungkin menghalang pertumbuhan sel-sel 
melalui mekanisme lain. Aktiviti perencatan kanser kolorektal oleh ekstrak dH2O dan 
EOH mungkin adalah melalui aktiviti anti-angiogenik mereka, kerana kedua-dua 
ekstrak ini menunjukkan kesan perencatan yang ketara terhadap spheroid tumor yang 
terdiri daripada sel-sel EA.hy926 dan HCT 116. Melalui kajian dok molekular, adalah 
didapati bahawa aktiviti anti-angiogenik ekstrak EOH boleh dikaitkan dengan hakitat 
bahawa ia mungkin mengandungi β-caryophyllene dan β-elemene, bahan-bahan kimia 
yang mempunyai potensi tinggi untuk menjadi perencat yang kuat terhadap HIF-1α, 
iaitu protein yang menggawal transkripsi VEGF. Sementara itu, aktiviti antioksidan 
dan antikanser ekstrak EOH mungkin disebabkan oleh kemungkinan kewujudan β-
caryophyllene. Ekstrak EOH daun jambu batu telah menunjukkan kesan-kesan anti-
angiogenik yang menjanjikan dalam kajian-kajian in vitro dan ex vivo. Oleh itu, kajian 
ini boleh disimpulkan bahawa ekstrak EOH mempunyai potensi dalam rawatan kanser 




THE POTENTIAL ANTICANCER EFFECTS OF PSIDIUM GUAJAVA 





 Colorectal cancer, which is the cancer that develops in the colon or rectum, is 
one of the most common cancers that lead to death. The prevalence of colorectal cancer 
in Malaysia is expected to increase due to the aging population, socioeconomic 
advances, and increasingly Westernised diet and lifestyle. The growth of colorectal 
tumours beyond a certain size, as well as their metastatic spread, is dependent on the 
increase in angiogenesis of their surrounding vasculature. As Psidium guajava (guava) 
leaves are rich in phenolic compounds, flavonoids, carotenoids, and vitamins, the anti-
angiogenic and anticancer activities of P. guajava leaf extracts were investigated to 
assess their potential in the treatment of the angiogenesis-dependent colorectal cancer. 
Three extracts were produced using distilled water, ethanol, and n-hexane as solvents, 
and were labelled as dH2O, EOH, and NH. The extracts were physically characterised 
through gas chromatography–mass spectrometry (GC-MS), ultraviolet-visible 
spectroscopy (UV-Vis), and Fourier transform infrared spectroscopy (FTIR). Through 
the DPPH radical scavenging, total phenolic content, and total flavonoid content 
assays, the EOH extract was found to have the highest antioxidant activity. The dH2O 
and EOH extracts exhibited more inhibitory activity against EA.hy926 (human 
vascular endothelial) cell viability and microvessel growth from rat aortic rings 
compared to the NH extract, indicating a better anti-angiogenic activity. In order to 
investigate the effects of the dH2O and EOH extracts on different aspects of the 
angiogenic process, the cell migration, tube formation, and colony formation assays 
xx 
 
were conducted using the EA.hy926 cells. The EOH extract performed significantly 
better than the dH2O extract against the cell migration and colony formation of the 
cells. Both extracts were also effective against tube formation, with the dH2O extract 
having a slightly higher inhibitory activity. Through the enzyme-linked 
immunosorbent assay (ELISA), the VEGF expression of the EA.hy926 cells was found 
to be inhibited by the EOH extract. The NH extract had a better inhibitory activity on 
the cell viability of the HCT 116 human colon carcinoma cell line, although the high 
IC50 values suggested that all three extracts were not cytotoxic towards the cancer cells, 
and the extracts may have inhibited the growth of the cells through other mechanisms. 
The colorectal cancer inhibitory activity of the dH2O and EOH extracts could have 
been through their anti-angiogenic activity, as the two extracts showed significant 
inhibitory effect on tumour spheroids consisting of EA.hy926 and HCT 116 cells. 
From the molecular docking studies, the anti-angiogenic activity of the EOH extract 
could be attributed to the fact that it may contain β-caryophyllene and β-elemene, 
which had a high potential to be a potent inhibitor to HIF-1α, a protein that mediates 
the transcription of VEGF. Meanwhile, the antioxidant and anticancer activities of the 
EOH extract could be due to the possible presence of β-caryophyllene. The EOH guava 
leaf extract had shown promising anti-angiogenic effect in vitro and ex vivo. Therefore, 
it can be concluded that the EOH extract has potential in the treatment of colorectal 











 Cancer, also known as malignant tumour and neoplasm, is no single disease, 
but a generic term for large family of diseases defined by abnormal cell growth beyond 
their usual boundaries, which could also potentially metastasize, invading adjoining 
body parts and spread to other organs. There are over 100 types of cancers that affect 
humans. 
 According to the World Health Organisation (WHO), cancer is the second 
leading cause of death globally, accounting for around 8.8 million deaths, which was 
one out of six deaths. Around 70% of cancer deaths occur in low- and middle-income 
countries. The Global Health Observatory estimated that 9.6 million deaths will be by 
cancer in 2018, and therefore is a global epidemic that needs to be addressed. The most 
common cancers that led to deaths in 2015 were cancers of the lungs, liver, bowels 
(colorectal), stomach, and breasts (World Health Organization (WHO), 2018). The 
most common types of cancers that affect males are cancers of the lungs, prostate, 
bowels, and stomach, while cancers of the breasts, bowels, lungs, and cervix are more 
common for females. For children, cancers of the lymphoid blood cells (leukaemia) 
and brain are more common (World Health Organization (WHO), 2014) (World 





1.1.1 Causes of Cancer 
 Most cases of cancer arose from the interaction between an individual’s genetic 
factor with environmental factors, with only a small amount of cases that were caused 
by inherited genetics (Anand et al., 2008). The cancer-causing environmental factors, 
known as carcinogens, can be separated into three types – physical, chemical, and 
biological. Physical carcinogens include ionizing radiation and non-ionizing 
ultraviolet radiation, and exposure to these types of radiation are related to the cause 
of some invasive cancers and most non-invasive cancers such as non-melanoma skin 
cancers. Exposure to chemical carcinogens, such as tobacco smoke and alcohol, could 
lead to specific types of cancer. Tobacco smoke, in particular, is highly correlated with 
incidences of lung cancer (Kuper et al., 2002), while numerous cases of liver and 
digestive tract cancers were attributed to alcohol exposure (Schütze et al., 2011). 
Biological factors that cause cancer mostly come from infections of the body by 
pathogens, usually viruses. Examples of these cancer-causing viruses, or oncoviruses, 
are the human papillomavirus that causes cervical cancer, and the hepatitis B and 
hepatitis C viruses that cause liver cancer. 
 Other than environmental factors, a small minority of cancers were caused by 




 The transformation from normal cells to cancer cells is caused by a series of 
genetic mutations in genes that regulate cell division, apoptosis, and DNA repair. 
According to researchers Douglas Hanahan and Robert Weinberg, tumour cells show 
3 
 
the “six hallmarks of cancer” – the characteristics necessary to produce malignant 
tumours as normal cells progress into the cancer disease, enabling tumour growth and 
metastasis. These characteristics include the sustained proliferation of the cells without 
the regulation of normal intercellular signals, continuous cell growth despite the 
presence of growth suppressors, resistance towards programmed cell death through 
apoptosis, immortality in terms of unlimited cycles of cell replication, the induction of 
angiogenesis for the production of new blood vessels to provide for the metabolic 
requirements of the cells with their unchecked growth, and the invasion of their 
surrounding tissues as well as metastasis to other organs  (Hanahan and Weinberg, 
2011). 
 
1.1.3 Colorectal Cancer 
 Colorectal cancer is also known as bowel cancer or colon cancer. It was 
responsible for 774 000 deaths in 2015 (World Health Organization (WHO), 2018). 
Colorectal cancer may lead to the narrowing or blockages of the bowel, which would 
affect the bowel habits of the patient. Symptoms of this disease include diarrhoea or 
constipation, blood in stool, abdomen pain and bloating, fatigue, or unexplained 
weight loss. 
 Most cases of colorectal cancer are caused by old age and lifestyle factors such 
as smoking (Liang et al., 2009), a lack of physical exercise (Harriss et al., 2009), and 
the consumption of red meat and processed meat (Larsson and Wolk, 2006) as well as 
alcohol (Cho et al., 2004) (Fedirko et al., 2011) (World Health Organization (WHO), 
2014). Those inflicted with inflammatory bowel diseases (Crohn’s disease and 
ulcerative colitis) had a greater risk of getting colorectal cancer. Less than 5% of cases 
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of colorectal cancer were caused by inherited genetic disorders such as hereditary non-
polyposis colon cancer, Gardner syndrome, and familial adenomatous polyposis 
(Lynch and De la Chapelle, 2003). The risk of developing colorectal cancer is high for 
a person with first-degree relatives (parent, sibling or child) diagnosed with it 
(Kampman, 2007).  
 Colorectal cancer is nearly three times more common in high-income countries 
than in middle- to low-income countries due to the higher life expectancy, as well as 
the Westernised diet. It is also slightly more common in men than in women by seven 
to five (Ferlay et al., 2010). In Asia, while cases of colorectal cancer is higher in 
developed countries such as Singapore, Japan, and South Korea (International Agency 
for Research on Cancer, 2012) (Sung et al., 2014), the socioeconomic advancement 
and increasingly Westernized life style in Malaysia is expected to heighten the 
incidences of colorectal cancer in the near future (Veettil et al., 2017). The prevalence 
of colorectal cancer risk would also increase in the future due to the aging of the 
Malaysian population (Yusoff and Zulkifli, 2014), as about 80% of the cases of 
colorectal cancer in Malaysia were diagnosed in people older than 50-years-old (Lim 
et al., 2008). In 2014, incidences of colorectal cancer among other types of cancer were 
the second highest in males (2 563 cases), and third in females (1 976). 
 
1.1.3(a) Pathogenesis of Colorectal Cancer 
 Tumours of colorectal cancer originate from the epithelial cells lining the colon 
or rectum of the gastrointestinal tract as the carcinogenic food and drinks that were 
ingested interact with their genetic factors. Cells that had experienced a mutation that 
increased the expression of their Wnt signalling pathway may develop into tumour 
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cells. Other mutations of signalling proteins responsible for cell apoptosis (Markowitz 
and Bertagnolli, 2009), as well as those for DNA repair, also contributed to the 
pathogenesis of colorectal cancer (Lynch and Hoops, 2002). 
 Colorectal cancer usually started out as a benign tumour, a polyp, which slowly 
became a malignant tumour over time. Around 95 % of the cases of colorectal cancer 
are formed from adenomatous polyps, with the rest being mucinous and 
adenosquamous (Kufe et al., 2010). Cancerous polyps could grow through its spread 
into the wall of the colon or rectum, starting from the innermost mucosa. They could 
also grow into blood or lymph vessels, then spread to distant parts of the body through 
them. 
 The genetic transition to malignant cells for colorectal cancer involves the 
sequential mutation of the ras gene that controls cell proliferation (Vogelstein et al., 
1988), and subsequent inactivation or loss of p53 (Baker et al., 1989) that codes for a 
tumour suppression protein, genetic alterations that are thought contribute to several 
malignant phenotypes and increased angiogenesis (Fearon and Vogelstein, 1990). 
These, and other genetic alterations, provide the cells with a growth advantage that 
allow them to outgrow other cells and form a tumour. 
 From adenomas, the cells gradually increase in size, undergo dysplasia, acquire 




Figure 1.1 Genetic changes in colorectal cancer progression (Fearon and Vogelstein, 




1.1.3(b) Treatment of Colorectal Cancer 
 Early stages of colorectal cancer could be treated with surgery, either through 
colonoscopy or the surgical removal of the infected part of the colon or rectum. 
Depending on the severity of a particular case, the treatment is sometimes 
accompanied with chemotherapy and radiation therapy to shrink the tumour before 
surgery, and to reduce the risks of recurrence after surgery. Targeted therapy, a type 
of chemotherapy with drugs such as bevacizumab and ramucirumab that specifically 
targets proteins contributing to cancer development, could also be used. Those with 
advanced colon cancer or with severe symptoms will be provided with palliative care 
to reduce the symptoms and complications, as well as to improve the quality of life 













 Angiogenesis is an important, multistep physiological process in which new 
blood vessels were formed from pre-existing ones. It is an essential physiological 
process during embryo development, wound healing, and in response to ovulation 
(Adair and Montani, 2010). This process includes the proliferation and migration of 
endothelial cells, the remodelling of the surrounding extracellular matrix, and the 
maturation of the new vessels formed (Kimura et al., 2000). The angiogenic process is 
tightly regulated, either activated or repressed through a balance between angiogenic 
and angiostatic stimuli as the metabolic requirements of the surrounding cells change. 
Changes in metabolic activity would lead to changes in vasculature through 
angiogenesis to provide for those requirements. 
 When unregulated, an overexpression of angiogenesis could result in severe 
tissue dysfunction and lead to the pathogenesis and development of a number of 
diseases, for example, rheumatoid arthritis (Paleolog, 2002), diabetic retinopathy 
(Crawford et al., 2009), and chronic inflammatory diseases such as atherosclerosis, 
rheumatoid arthritis, and inflammatory bowel diseases (Koutroubakis et al., 2006). In 
addition, angiogenesis is a vital requirement for the metastasis of tumours. The reverse 
condition, insufficient vessel growth or abnormal vessel regression, would lead to or 
contribute to the severity of diseases as well, diseases such as cardiac and cerebral 
ischemia (Krupinski et al., 1994), hypertension (Struijker, 1999), and osteoporosis 
(Martinez et al., 2002). In contrast to physiological angiogenesis, with a vasculature 
that is well-ordered in structure and function, pathologically-induced angiogenesis 
form a vasculature that is not distributed uniformly, branch irregularly or excessively, 
and do not follow a clear hierarchy (Dvorak, 2005). This could have been due to an 
imbalance of angiogenic regulators or because they were the result of the activity of 
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molecular signals different from physiological angiogenesis. Also, unlike 
physiological angiogenesis, pathological angiogenesis is often induced by some 
degree of inflammation due to the recruitment of blood-borne inflammatory and 
angiogenic factors to sites of inflammation and wound healing (Carmeliet, 2000b). 
 Vasculogenesis is another physiological process which involves the formation 
of new blood vessels. However, while similar to angiogenesis, it is a distinct process, 
responsible for the formation of blood vessels de novo from endothelial cell precursors 
in the developing embryo where there were previously none. After that angiogenesis 
takes over the blood vessel formation process with the growth, expansion, and 
remodelling of these primitive vessels to form a vast, complex vascular network 
(Conway et al., 2001). 
 
1.2.1 Sprouting Angiogenesis 
 The two types of angiogenesis that were identified, sprouting angiogenesis and 
intussusceptive (non-sprouting) angiogenesis (Ribatti, 2006), involve different cell 
types and are regulated by biological different molecules. Sprouting angiogenesis is 
the formation of new blood vessels through the ends of pre-existing ones, characterised 
by local vasodilation, increased vascular permeability, and cell proliferation (Djonov 
et al., 2003). Vasodilation for sprouting angiogenesis is initiated during hypoxia in 
response to nitric oxide (NO) in order to cater to the metabolic requirements of the 
cells in the region. In` most parenchymal cells, the transcription of vascular endothelial 
growth factor A (VEGF-A), a type of signalling protein that stimulates angiogenesis, 
is in part up-regulated by NO in response to a hypoxic environment. Numerous other 
angiogenic factors, such as angiopoietin 2 (Ang-2) (Yamakawa et al., 2003) and 
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inducible nitric oxide synthase (iNOS) (Melillo et al., 1995), are also up-regulated in 
response to hypoxia. Some of the roles of VEGF-A in angiogenesis include inducing 
increased vascular permeability, promoting alterations in the cell membrane structure 
(Kimura et al., 2000), and most importantly, as a pro-angiogenic stimulant that guides 
the growth of the new capillary sprout that would eventually form the new vessel. 
Therefore, the role of VEGF-A is irreplaceable in hypoxia-induced angiogenesis 
(Adair and Montani, 2010).  
 Through the redistribution of intercellular adhesion molecules and alterations 
in cell membrane structure, an increase in vascular permeability in response to NO is 
achieved (Eliceiri et al., 1999). The glycoprotein angiopoietin 2 (Ang-2) played a part 
in the reduction of inter-endothelial cell contacts, detaching the smooth muscle cells 
and loosening the underlying matrix for the migration of the endothelial cells (Gale 
and Yancopoulos, 1999). Through the degradation of the extracellular matrix, other 
growth factors involved in angiogenesis and cell proliferation such as the basic 
fibroblast growth factor (bFGF) and over 20 matrix metalloproteinases (MMPs) were 
liberated, along with exposing the adhesion sites hidden in the matrix (Conway et al., 
2001). The MMPs are crucial in the degradation of the extracellular membranes and 
basement membrane structures, and are in part involved in endothelial sprouting 
through their interactions with other angiogenic factors (Pozzi et al., 2000). 
 With an increase in vessel permeability and the degradation of the surrounding 
matrix, the endothelial cells are free to migrate to form new vessels, a process mediated 
by various forms of VEGF, angiopoietins, and FGFs. FGFs are capable of stimulating 
endothelial cell growth and recruit inflammatory cells that produce an array of 
angiogenic factors (Carmeliet, 2000a). A chemotactic gradient of VEGF-A is produced, 
from the area with oxygen-starved cells to the pre-existing vessels. Endothelial cells 
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from the pre-existing vessels form sprouts that grow following the gradient, guided by 
endothelial tip cells with filopodia heavily endowed with VEGFR2 receptors capable 
of sensing differences in VEGF-A concentrations (Gerhardt et al., 2003). Endothelial 
stalk cells would then proliferate as they follow behind the tip cell following the 
VEGF-A gradient, which is how the capillary sprouts grow and elongate. The series 
of stalk cells would become the lumen of the new capillaries as their vacuoles develop 
and coalesce.  
 VEGF-A levels would return to normal when the local tissue had received an 
adequate amount of oxygen from the new capillaries. The new capillaries would then 
mature and stabilise through the recruitment of pericytes and the deposition of the 
extracellular matrix produced by mural cells (Adair and Montani, 2010). The 
surrounding vascular smooth muscle cells stabilise the new vessels through the 
inhibition of endothelial proliferation and migration, as vessels not covered by the 
smooth muscle cells could easily regress when angiogenic stimuli become limiting 
(Benjamin et al., 1998). The extracellular matrix functions as a scaffold on which the 
new vessels grow, and as a local store for growth factors that can be activated rapidly 
without de novo synthesis (Li et al., 2003). The pericytes that surround the endothelial 
cells of the vessels assist in the function specialisation of the vessels to accommodate 
local tissue vasculature requirements through their expression of numerous growth 





1.2.2 Intussusceptive Angiogenesis 
 Compared to sprouting angiogenesis, the intussusceptive mode of the 
angiogenic process is a fairly-recent discovery. It was first observed in the developing 
microvasculature of the postnatal rat lung by Burri and coworkers in 1987 using 
scanning electron microscopy. Intussusceptive angiogenesis is a process that occurs 
with decreasing frequency in the vascular bed of vertebrates from birth to adulthood, 
as it was more frequently observed in prenatal and new-born rat myocardium than 
those in adults (van Groningen et al., 1991). Recently, intussusceptive microvascular 
growth has been observed to be involved in the capillary network expansion of 
numerous organs and species, including the chicken chorio-allantoic membrane (CAM) 
(Patan et al., 1993) (Djonov et al., 2000), retina, kidney (Djonov et al., 2002), rat 
myocardium (van Groningen et al., 1991), rat cerebrum (Zhang et al., 2002), and 
tumours (Djonov et al., 2001) (Patan et al., 2001). 
 The process of intussusceptive angiogenesis involves the extension of the 
blood vessel wall into the vessel to split it longitudinally into two, and can be divided 
into four distinct phases. In the first phase, an interendothelial bridge is formed through 
the creation of a zone of direct contact between opposing capillary walls protruding 
into the lumen. This is followed by the second phase, with the formation of a central 
perforation of the endothelial bilayer and the reorganisation of the intercellular 
junctions of the endothelium. The cylindrical bridge is wrapped in endothelial cells, 
with the presence of cytoplasmic extensions of myofibroblasts with their 
microfilaments within the core of the bridge. Next, an interstitial pillar core is formed 
through successive invasions of myofibroblasts and pericytes, and the deposition of 
interstitial fibres. Finally, in the last stage, the pillar increases in girth into a full-sized 
capillary mesh (Burri and Tarek, 1990) (Burri et al., 2004).  
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 Intussusceptive angiogenesis is activated through friction in the vessel system 
from blood flow-induced shear stress and pressure induced-wall stress from blood flow, 
vasodilation, and blood pressure (Tomanek, 2012). Blood vessels with higher 
velocities of blood flow had been shown to induce intussusceptive angiogenesis in 
chick embryos (Thoma, 1893). The time needed for pillar formation is about 40 to 120 
minutes, a rapid process that infers that the means and mechanisms required for 
transluminal pillar formation is constantly present and only needs to be switched on in 
the endothelial and supporting cells, with no alteration of gene expression required 
(Djonov et al., 2002). 
 As sprouting angiogenesis involves sprouts of endothelial cells growing 
towards the pro-angiogenic stimulus VEGF-A, blood vessels could be created in areas 
that were previously devoid of them through this type of angiogenesis. In contrast, 
intussusceptive angiogenesis can only occur when there are pre-existing vessels in the 
area, as transvascular pillar tissues were formed through the invasion of interstitial 
tissues into the existing vessels (Adair and Montani, 2010). However, the process of 
intussusceptive angiogenesis is much faster than that of sprouting angiogenesis, as it 
does not require endothelial proliferation and migration, but only the reorganisation of 
existing endothelial cells. Intussusceptive angiogenesis is therefore more 
metabolically efficient, and more suited for situations where fast growth is needed but 
resources are limited. Intussusceptive angiogenesis is not only involved in numerous 
organs at different levels of the systems, it may also be involved in the vascular 
structure remodelling to optimise vessel form and function, as the same process of 
pillar formation, termed intussusceptive arborisation, has been observed in the initial 
remodelling of primitive capillary plexuses into complex arterial and venous vascular 
trees (Kurz et al., 2003). 
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1.2.3 Biological Molecules Involved in the Angiogenic Process 
Table 1.1 Angiogenesis activators and inhibitors involved in the angiogenic process. 
Angiogenesis Activators Angiogenesis Inhibitors 
Angiopoietin-1 (Ang-1)  Angiopoietin-1 (Ang-1) (tumour 
angiogenesis) 
Angiopoietin-2 (Ang-2) (in the presence 
of VEGF) 
Angiopoietin-2 (Ang-2) (in the absence 
of VEGF) 
Basic fibroblast growth factor (bFGF) Vascular endothelial growth factor 
receptor (VEGFR) 
Basic fibroblast growth factor (bFGF) Endostatin 
Cyclooxygenase-2 (COX-2) Metallopeptidase inhibitor 1 (TIMP1) 
Hepatocyte growth factor (HGF) Interferon-α, -β, and -γ (IFN-α, -β, and –
γ) 
Hypoxia-inducible factor 1-alpha (HIF-
1α) 
Interleukin-4, -12, and -18 (IL-1, -12, 
and -18) 
Interleukin-1 (IL-1)  
Matrix metalloproteinase (MMP)  
Nuclear factor kappa-B (NF-κB)  
Placental growth factor (PlGF)  
Platelet-derived growth factor (PDGF)  
Tumour necrosis factor-α (TNF-α)  




 While numerous biological molecules were involved in the angiogenic process, 
special attention has been given to VEGF as the primary inducer of blood vessel 
formation in adults. Not only does it function as a key regulator of physiological and 
pathological angiogenesis associated with a number of diseases, it also has a direct 
mitogenic effect on endothelial cells (Thomas, 1996) (Shibuya, 2006). VEGF-A 
consists of many isoforms through alternative splicing, and they exert many of the 
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same functions in the angiogenic process such as increasing vascular permeability, 
stimulating endothelial cell proliferation and migration, and up-regulating the 
transcription factors of proteins associated with angiogenesis such as chemokine (C-
X-C motif) ligand 2 (CXCL2), IL8, cyclooxygenase-2 (COX-2,) and the tissue factors. 
(Carmeliet and Collen, 1999). The predominant isoform of VEGF secreted by most 
normal and transformed cells is VEGF165, which exhibits biochemical properties 
similar to VEGF purified from various sources (Ferrara et al., 1992). During hypoxia, 
an up-regulation in VEGF expression, through the increased transcription and 
stabilisation of its mRNA, was induced (Mukhopadhyay et al., 1995) (Ikeda et al., 
1995). When VEGF-A binds with the VEGFR-2 receptors on endothelial cells, a 
cascade of signalling events is triggered, resulting in the phosphorylation and 
activation of proteins related to angiogenesis. VEGF-A triggers progenitor cells to 
differentiate towards the endothelial cell lineage, guides the angiogenic sprouting of 
endothelial tip cells (Gerhardt et al., 2003), stimulates the three-dimensional vascular 
tube formation, and regulates vascular permeability (Ferrara et al., 2003). The blocking 
of VEGF significantly decreases microvessel outgrowth (Brown et al., 1996). 
 The transcription factor subunit hypoxia-inducible factor 1-alpha (HIF-1α) is a 
major regulator of the cellular and developmental responses to hypoxia. During 
hypoxia, the protein degradation of HIF-1α via the ubiquitin protease pathway is 
prevented. The stabilised HIF-1α subunit is then free to merge with the β subunit, 
leading to the induction of the transcription of more than 60 genes, including 
angiogenic promoters VEGF (Wang et al., 1995) and angiopoietin-2 (Ang-2) (Simon 
et al., 2008), as well as matrix metalloproteinases-2 (MMP-2) that mediates the 
migration of endothelial cells in the angiogenic process (Ben-Yosef et al., 2005). 
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 The basic fibroblast growth factor (bFGF) is another pro-angiogenic growth 
factor that is up-regulated during active angiogenesis. Normally stored in the vascular 
basement membrane and extracellular matrix, it can be activated by heparan sulfate-
degrading enzymes to promote angiogenesis during wound healing and tumour 
development. It induces angiogenesis by increasing the proliferation of endothelial 
cells as well as their chemotaxic organisation into tube-like structures for the formation 
of new blood vessels, and its production of proteases involved in angiogenesis 
(Montesano et al., 1986).  
 The placental growth factor, or PlGF, is an angiogenic protein from the VEGF 
family that stimulates the growth, migration, and survival of endothelial cells (Ziche 
et al., 1997) (Adini et al., 2002), and also induces vasodilatation and vessel growth 
(Yonekura et al., 1999). While it is primarily expressed in the placenta throughout all 
stages of gestation, transcripts of PlGF have also been detected in the heart, lungs, 
thyroid glands, and skeletal muscles (Persico et al., 1999). PlGF and its corresponding 
receptor, VEGFR-1, are expressed minimally in the adult quiescent vasculature, but 
both of them are strongly up-regulated in pathological conditions (Carmeliet et al., 
2001). Even though human PlGF-1 and VEGF-A are only 42% identical in terms of 
amino acid sequence identity, their overall three-dimensional structures are highly 
similar (Iyer et al., 2001), which explains the fact that they competitively bind to the 
same receptor and have similar biological functions. PlGF was found to function in the 
stimulation of the growth and migration of endothelial cell in vitro, and the ex vivo 
angiogenesis in rabbit avascular cornea with the same potency of those induced by 
VEGF and basic fibroblast growth factor (bFGF) (Ziche et al., 1997). By competing 
with VEGF-A for VEGFR-1 binding sites, more VEGF-A is available to bind to 
VEGFR-2, which amplifies the VEGF-A-driven signal for angiogenesis. In addition, 
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PlGF is also capable of triggering its own pro-angiogenic signalling cascade via 
VEGFR-1, acting on the growth, migration, and survival of endothelial cells (Ziche et 
al., 1997) (Autiero et al., 2003). PlGF was also found to be over-expressed in various 
cells during pathological conditions, such as in colorectal (Wei et al., 2005) and human 
breast cancer cells (Parr et al., 2005). 
 The activation of nuclear factor kappa-B (NF-κB), a type of protein complex 
that controls DNA transcription, is a significant event in the angiogenic process, as it 
regulates genes involved in cell survival, cell growth and migration, and the MMPs. 
NF-κB mediates the synthesis of cytokines tumour necrosis factor-α (TNF-α), IL-1β, 
IL-6, and IL-8, as well as the expression of COX-2. In the angiogenic process, NF-κB 
promotes the expression of MMP-2, -3, and -9 involved in the degradation of the 
vascular basement membrane and the remodelling of the extracellular matrix (Popov 
et al., 2006). The activation of NF-κB was found to be able to enhance the VEGF 
production in mouse lung epithelial cells through the hypoxia-induced mitogenic 
factor (HIMF) (Tong et al., 2006), thus promoting angiogenesis. 
 The angiopoietin/Tie2 system is an important regulator of angiogenesis. 
Angiopoietins, a family of extracellular ligands, exert their functions in vascular 
remodelling and angiogenesis. Together with VEGF, angiopoietin-1 (Ang-1) 
stimulates the production of pro-angiogenic cytokines in ex vivo rat aortic rings 
explants before the emergence of neovessels (Aplin et al., 2006), which could be due 
to both molecules being able to activate the Tie-2 receptor. Moreover, Ang-1 promote 




 Angiopoietin-2 (Ang-2) is an antagonist of Ang-1 in its binding with the Tie-2 
receptor and a regulator of angiogenesis (Fiedler et al., 2003). It acts as a pro-
angiogenic in the presence of VEGF, functioning in the destabilising of mature blood 
vessels in the angiogenic process before vessel sprouting could occur (Scharpfenecker 
et al., 2005),  but acts as an anti-angiogenic signal in the absence of VEGF in inducing 
vessel regression (Lobov et al., 2002) . The competitive binding of Ang-2 to the Tie-2 
receptor blocks the function of Ang-1 and sensitizes endothelium cells to TNF-α 
signals, which promotes endothelial cell survival, vessel sprouting, and angiogenesis 
(Maisonpierre et al., 1997). Through the destabilisation of the blood vessels, the 
endothelial cells are released from the pericytes and the extracellular matrix (Holash 
et al., 1999). In addition, Ang-2 sensitizes endothelial cells to VEGF, which leads to 
increased angiogenesis. The gene expression of Tie2-expressing monocytes can be 
regulated by Ang-2 to augment pro-angiogenic activities (Coffelt et al., 2010).  
 TNF-α is a pro-inflammatory cytokine secreted by monocytes in response to 
tissue injury, which also has the ability to induce the gene expression of VEGF and its 
receptors, leading to an increase of angiogenesis (Giraudo et al., 1998). TNF-α could 
also contribute to local angiogenesis by stimulating the release of VEGF, basic 
fibroblast growth factor (bFGF) (Ryuto et al., 1996), and platelet-derived growth factor 
(PDGF) (Rosengren et al., 2010), which promotes the proliferation and migration of 
endothelial cells. 
 Like TNF-α, IL-1 is a cytokine that is also a potent pro-angiogenic stimulus in 
both physiological and pathological angiogenesis. IL-1 activates the myeloid cells to 
produce a cascade of cytokines, which in turn activates the endothelial cells, and 
induces changes in their gene expression, function, and morphology towards increased 
angiogenesis (Voronov et al., 2007). It induces the migration of the endothelial cells 
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and tube formation through the activation of  the p38-mitogen-activated protein kinase 
(MAPK) and the MAPK-activated protein kinase 2 (Jagielska et al., 2012), and also 
up-regulates the expression of VEGF and its receptors on endothelial cells, both of 
which also leads to increased angiogenesis (Berse et al., 1999). 
 COX-2 is an enzyme that can be induced by hypoxia and cytokines such as 
VEGF (Goppelt-Struebe, 1995). The down-regulation of COX-2 significantly 
inhibited the in vitro migration and tube formation of human umbilical vein endothelial 
(HUVEC) cells through the suppression of the angiogenesis-related molecules VEGF, 
Flt-1, Flk-1/KDR, ANG-1, Tie-2, and MMP-2 (Yao et al., 2011). The expression of 
COX-2 correlated with the levels of VEGF and PDGF expression in multiple gastric 
adenocarcinoma cell lines, further shown by the increased microvessel density 
(Tatsuguchi et al., 2004). 
 The hepatocyte growth factor (HGF) is a cellular growth, motility, and 
morphogenic factor secreted by mesenchymal cells (Sonnenberg et al., 1993). It is also 
a potent angiogenic factor that stimulates angiogenesis in the in vitro wound healing 
and three-dimensional collagen assays using human endothelial cells, and induces 
neovascularisation in the in vivo rabbit cornea assay at sub-nanomolar concentrations 
(Bussolino et al., 1992). It stimulates the cell migration, proliferation, protease 
production, and the invasion and organisation of vascular endothelial cells into 
capillary-like tubes (Rosen et al., 1997). 
 MMPs, also called also called matrixins, are calcium-dependent zinc-
containing endopeptidases involved in the degradation of the extracellular matrix and 
the tissue remodelling process (Verma and Hansch, 2007). Currently, there are 23 
MMPs identified in humans (Visse and Nagase, 2003). Many of them, such as MMP-
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1 and MMP-7, are expressed in physiological situations involving angiogenesis. 
Biological molecules such as TNF-α and interleukins (ILs) stimulate MMP expression. 
The MMPs would then degrade the ECM and recruit inflammatory cells to mediate 
the adhesion, proliferation, and apoptosis of the cells in vessel walls for vascular 
remodelling (Parks et al., 2004).  
 
1.2.4 Angiogenesis in the Treatment of Colorectal Cancer 
 Sustained angiogenesis is one of the characteristics of tumour cells, as the 
growth of blood vessels around the tumour was stimulated in order to supply nutrients 
to the tumours.  It is a vital step in a tumour’s development towards malignancy as it 
allows for tumour propagation and progression (Folkman, 1995). As the blood vessels 
surrounding the tumour supply the cancerous cells with the oxygen and metabolites 
they require, as well as serve as an effective system for cellular waste disposal, the 
growth of the vasculature system surrounding the tumour is the rate-limiting step for 
tumour progression (Bergers and Benjamin, 2003).  
 In order for tumours to grow beyond sizes of about 1-2 mm in diameter, the 
switch to the angiogenic phenotype is required. It consists of a gain-of-function event 
where pro-angiogenic factors are up-regulated or induced in the tumour cells, and loss-
of-function events where endogenous angiogenic inhibitors are down-regulated 
(Hanahan and Folkman, 1996). Without switching to a sustained pro-angiogenic state, 





 The increased tissue mass from the formation of the tumour causes hypoxia at 
the surrounding tissue microenvironment, activating the hypoxia-inducible factor-1α 
(HIF-1α) which in turn up-regulates the expression of pro-angiogenic factors that lead 
to increased angiogenesis (Dor et al., 2001). Angiogenesis is also activated through 
the cancer cell-driven expression of pro-angiogenic molecules such as VEGF, bFGF 
(Dirix et al., 1996), IL-8 (Sparmann and Bar-Sagi, 2004), placenta-like growth factor 
(PLGF) (Wei et al., 2005), PDGF (Saito et al., 2000), transforming growth-factor-β 
(TGF-β) (Tsushima et al., 1996), pleiotrophin and more (Relf et al., 1997), 
biomolecules that correlate with a decrease in the survival rate of colorectal cancer 
patients. Oncogenes such as such as K-ras (Okada et al., 1998), v-Src (Jiang et al., 
1997), c-Src (Mukhopadhyay et al., 1995), v-raf, c-fos,(Mazure et al., 1996) and v-yes 
could also be expressed by the tumour to up-regulate angiogenic factors and induce 
angiogenesis (Kerbel et al., 1998). Growth factors such as VEGF, TGF-α and -β, bFGF, 
HGF, Ang-1 and -2, and IL-8 had been identified to have possible tumour 
angiogenesis-promoting activity (Bouck et al., 1996).  
 One of the most common genetic changes in human cancers involve the ras 
gene, results in elevated VEGF (Rak et al., 1995), bFGF (Iberg et al., 1989), TGF-α 
and TGF-β (Cleveland et al., 1980) (Roberts et al., 1986) in transformed epithelial cells, 
which leads to elevated tumour angiogenesis in addition to increased tumour cell 
proliferation. A reduction in VEGF activity was associated with the disruption of the 
mutant K-ras allele in human colon cancer DLD-l and HCT l16 cells, as well as a 
significantly more active induction of mitogenesis in HUVEC cells (Shirasawa et al., 
1993) (Rak et al., 1995). It may explain the relevance of the timing of the ras gene 
mutation with the rapid disease progression of colorectal cancer (Fearon and 
Vogelstein, 1990) and the high frequency of K-ras mutation detected in polyploidy 
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colon tumours (Hasegawa et al., 1995). Elevated levels of TGF-α (Buick et al., 1987) 
and TGF-β (Jamal et al., 1994) expression were associated with ras oncogene 
mutations. Both TGF-α and –β are capable of inducing angiogenesis in vivo, and could 
also up-regulate VEGF, which leads to increased angiogenesis. Cells with the mutant 
oncogene v-src becomes tumourigenic and express high levels of VEGF mRNA and 
protein in a way similar to cells with H-ras mutations (Rak et al., 1995). 
 Mutations of the p53 tumour suppressor gene, which commonly occur during 
the genetic transformation of colorectal carcinomas, causes an up-regulation of the 
mRNA of VEGF (Kieser et al., 1994). The wild-type p53 gene regulate the expression 
of angiogenic inhibitor genes such as thrombospondin (Dameron et al., 1994) and the 
glioblastoma-derived angiogenesis inhibitory factor (Van Meir et al., 1994), as well as 
mediate apoptosis, cell mediation, and tumourigenicity (Donehower and Bradley, 
1993) (El-Deiry et al., 1992). 
 VEGF is a major factor in tumour angiogenesis, as numerous types of cancers 
and malignant melanomas, such as those of the breast, colon, ovary, bladder, and brain, 
were found to produce it. The blood vessels of these tumours were also found to 
express high levels of VEGF receptors (Dvorak et al., 1995) (Ferrara, 1995). The 
degree of vascularisation of cancer tumours had been closely associated with VEGF 
mRNA expression (Plate et al., 1992). The VEGF produced by the tumour cells were 
not only localised in the tumour but also in the vasculature (Plate et al., 1992) (Brown 
et al., 1993), which indicates that tumour-secreted VEGF accumulates in the target 
cells. The mRNA of VEGF receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) 
was also found to be up-regulated in the endothelial cells of tumour vasculature 
compared to those surrounding tumour-free tissue (Plate et al., 1992). As tumour cells 
that express VEGF possess a growth advantage in vivo due to their stimulation of 
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angiogenesis, yet the expression of VEGF did not confer a growth advantage for 
tumour cells in vitro, it can be inferred that VEGF’s role in tumour angiogenesis is due 
to paracrine rather than autocrine mechanisms (Ferrara, 1995). Treating nude mice 
bearing liver metastasis tumours of human colon carcinoma cells with anti-VEGF 
monoclonal antibodies resulted in a marked decrease in number and size for the 
tumours, with most of the tumours under 1 mm in diameter and all under 3 mm 
(Warren et al., 1995), which supports the hypothesis that the growth of tumours beyond 
a certain size requires angiogenesis for support. 
 The HIF-α transcriptional protein subunit was found to be overexpressed in 
numerous cancers and their metastases, including cancers of the colon, breast, kidney, 
prostate, lung, skin, ovary, and pancreas (Zhong et al., 1999). Blood vessels produced 
from tumour angiogenesis are highly irregular and leaky compared to regular vessels, 
which leads to the presence of hypoxic areas in the tumour as well as increased HIF-
1α stability despite active angiogenesis. Oncogenes from ras and p53 mutations, such 
as those in colorectal cancer, also contributes to the stabilisation of the HIF-1α protein 
subunit (Kikuchi et al., 2009) (Ravi et al., 2000). Since the HIF-1α is mediates the 
transcription of numerous genes associated with tumour angiogenesis and metastasis, 
it is an appealing target for anticancer strategies. 
 The overexpression of COX-2 contributes to the development of colorectal 
cancer through its promotion of VEGF activity in tumour angiogenesis (Cianchi et al., 
2001). High microvessel density around the tumour, as well as increased VEGF 
expression, correlates to the clinical stage progression of the disease in patients 
(Nakasaki et al., 2002), in addition to poor relapse-free survival rate and overall 
survival rate of colorectal cancer (Des Guetz et al., 2006). High vessel counts in 
colorectal cancer also correlates with hematogenous metastasis, as an increase in 
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tumour neovascularization also increases the surface area for tumour cells to 
potentially enter the systemic circulation and lead to metastasis (Folkman, 1994). 
 The final stage of oncogenesis is the metastasis of the tumour. 
Neovascularisation of the tumour from increased angiogenesis also increases the 
chances of the tumour cells entering the bloodstream and travelling to other distant 
organs. 
 Suppressing the growth of blood vessels surrounding the tumour, rather than 
the tumour itself, is a promising new approach to cancer therapy as the target cells are 
much more stable genetically, and therefore less likely to develop mutations that would 
lead to drug resistance (Kerbel and Folkman, 2002). Not only could anti-angiogenic 
drugs inhibit the growth of new microvessels surrounding the tumour, they also could 
induce the regression of recently-developed microvessels, which leads to either the 
arrestment of growth or apoptotic death of the tumour cells (Holmgren et al., 1995). 
Anti-angiogenic therapy could also be useful in the prevention of cancer in patients 
with high-risk of developing cancer or the recurrence of cancer, as well as in the 
prevention of cancer metastasis.  
 The antiangiogenic drug bevacizumab is a monoclonal antibody against VEGF. 
It is often added to the first line therapy of colorectal cancer, and has been shown to 
both prolong progression-free survival and overall survival of the patients (Wagner et 
al., 2009). Slow-growing tumours are harder to treat using chemotherapy, but was 
shown to respond better to anti-angiogenic therapies (Kerbel and Folkman, 2002). 
With the addition of bevacizumab to fluorouracil-based combination chemotherapy in 
the treatment of metastatic colorectal cancer, an improvement of response rate, median 
time to disease progression, and patient survival was recorded (Hurwitz et al., 2004). 
